RxDoctor Payments Data

Kenneth Osorio, MD

Phlebology · Mesa, AZNPI 1245229087

Payments from drug & device makers

$1,343in general payments, 2019–2025

Across 42 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$386
  • Tactile Systems Technology Inc$305
  • Medtronic$160
  • Bard Peripheral Vascular, Inc.$150
  • Angiodynamics, Inc.$145
  • Boston Scientific$59
  • plus $138 from 5 others

What the payments were for

  • Speaking & faculty fees$24218%
  • Food & beverage$1,10282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$386
Tactile Systems Technology Inc14$305
Medtronic5$160
Bard Peripheral Vascular, Inc.1$150
Angiodynamics, Inc.2$145
Boston Scientific3$59
Hydrofera LLC1$33
Koya Medical, Inc.1$31
E.r. Squibb & Sons, L.L.C.2$30
Pfizer2$30
Smith+Nephew1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few phlebology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$919,882
Medicare patients
409
Services billed
3,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enoxaparin Sodium31$1,810

Paid to pharmacies, not to this prescriber.

Other phlebology in Mesa

Where these figures come from

Is this you, or does something look wrong? →